CAS No.57576-44-0,Aclarubicin Suppliers

Products Categories

Pharmaceutical (30)
Organic Chemicals (10)
Others (7)
Reagent (2)
Materials (1)

Basic Information

Molecular Structure:
CAS No.:	57576-44-0
Name:	Aclarubicin
Article Data:	1

Formula:	C₄₂H₅₃NO₁₅
Molecular Weight:	811.881
Synonyms:	1-Naphthacenecarboxylicacid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]-3-(dimethylamino)-a-L-lyxo-hexopyranosyl]oxy]-,methyl ester, [1R-(1a,2b,4b)]-;Aclacinomycin A;Aclacur;Aclarubicin;Antibiotic3082A;Antibiotic 77-3082A;Antibiotic MA 144A1;Jaclacin;NSC 208734;
EINECS:	260-824-3
Density:	1.42 g/cm³
Melting Point:	151-153 °C
Boiling Point:	897.676 °C at 760 mmHg
Flash Point:	496.696 °C
Solubility:	Soluble in chloroform or ethyl acetate, insoluble in n-hexane, ether or petroleum ether
Hazard Symbols:	T
Risk Codes:	25
Safety:	36/37/39-45
Transport Information:	UN 3249
PSA:	217.05000
LogP:	3.15770

Synthetic route

: 16234-96-1
(+)-aklavinone

A: 57576-44-0
aclacinomycin A

B: aclacinomycin X

Conditions

Conditions	Yield
With soybean meal; dipotassium hydrogenphosphate; D-glucose; KE303 of S. galilaeus MA144-M1; magnesium sulfate; copper(II) sulfate; iron(II) sulfate; zinc(II) sulfate; sodium chloride; manganese(ll) chloride; starch; yeast extract In water at 28℃; for 96h;

: 57576-44-0
aclacinomycin A

: 16234-96-1
(+)-aklavinone

Conditions

Conditions	Yield
With hydrogenchloride In water at 90℃;	100%

: 69489-87-8
D-galactonic acid hydrazide

: 57576-44-0
aclacinomycin A

: C48H65N3O20

Conditions

Conditions	Yield
In dimethyl sulfoxide at 20℃; for 1h; Inert atmosphere;	35%

: 57576-44-0
aclacinomycin A

: 11-deoxy-β-rhodomycin A

Conditions

Conditions	Yield
With aclacinomycin-10-hydroxylase from streptomyces purpurascens Reagent/catalyst; Enzymatic reaction;

: 57576-44-0
aclacinomycin A

: C50H71NO16Si2

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: hydrogenchloride / water / 90 °C 2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / -20 °C / Molecular sieve View Scheme

: 57576-44-0
aclacinomycin A

: C44H53NO17

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: hydrogenchloride / water / 90 °C 2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / 0.5 h / -20 °C / Molecular sieve 3: 2,3-dicyano-5,6-dichloro-p-benzoquinone / dichloromethane; aq. phosphate buffer / 1.5 h / 0 °C / pH 7 View Scheme

: 57576-44-0
aclacinomycin A

: 7-[2-deoxy-3,4-tetraisopropyldisiloxyl-α-L-fucopyranosyl-(1→4)-3-amino-2,3-dideoxy-α-L-fucopyranoside]-aklavinone

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: hydrogenchloride / water / 90 °C 2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / -20 °C / Molecular sieve 3: 1,3-dimethylbarbituric acid; tetrakis(triphenylphosphine) palladium(0) / dichloromethane / 0.5 h View Scheme

: 57576-44-0
aclacinomycin A

: 7-[2-deoxy-α-L-fucopyranosyl-(1→4)-3-amino-2,3-dideoxy-α-L-fucopyranoside]-aklavinone

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: hydrogenchloride / water / 90 °C 2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / -20 °C / Molecular sieve 3: 1,3-dimethylbarbituric acid; tetrakis(triphenylphosphine) palladium(0) / dichloromethane / 0.5 h 4: pyridine; pyridine hydrofluoride / 0 °C View Scheme

: 57576-44-0
aclacinomycin A

: C52H61NO18

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: hydrogenchloride / water / 90 °C 2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / 0.5 h / -20 °C / Molecular sieve View Scheme

: 57576-44-0
aclacinomycin A

: 3',3'-didesmethyl-aclarubicin

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1: hydrogenchloride / water / 90 °C 2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / 0.5 h / -20 °C / Molecular sieve 3: 2,3-dicyano-5,6-dichloro-p-benzoquinone / dichloromethane; aq. phosphate buffer / 1.5 h / 0 °C / pH 7 4: 1,3-dimethylbarbituric acid; tetrakis(triphenylphosphine) palladium(0) / dichloromethane / 0.25 h / Inert atmosphere View Scheme

Yield

Multi-step reaction with 4 steps
1: hydrogenchloride / water / 90 °C
2: (triphenylphosphine)gold(I) chloride; silver(I) triflimide / dichloromethane / 0.5 h / -20 °C / Molecular sieve
3: 2,3-dicyano-5,6-dichloro-p-benzoquinone / dichloromethane; aq. phosphate buffer / 1.5 h / 0 °C / pH 7
4: 1,3-dimethylbarbituric acid; tetrakis(triphenylphosphine) palladium(0) / dichloromethane / 0.25 h / Inert atmosphere
View Scheme

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:44 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 57576-44-0

Specification

The Aclarubicin, with the CAS registry number 57576-44-0, is also known as Aclacinomycin A. It belongs to the product categories of Interferes with DNA Synthesis; Antibiotics; Antibiotics A to; Antibiotics A-F Antibiotics; Antibiotics by Application; Antineoplastic and Immunosuppressive Antibiotics Antibiotics; Mechanism of Action; Antitumour. Its EINECS number is 260-824-3. This chemical's molecular formula is C₄₂H₅₃NO₁₅ and molecular weight is 811.87. What's more, its systematic name is Methyl (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-1-naphthacenecarboxylate. This chemical is the second generation anti-tumor antibiotic and cell cycle nonspecific. It can restrain DNA and RNA protein. And it, as Anti-tumor antibiotic, is mainly used for lung, breast, gastrointestinal cancer, acute leukemia.

Physical properties of Aclarubicin are: (1)ACD/LogP: 3.987; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): 1.63; (4)ACD/LogD (pH 7.4): 1.75; (5)ACD/BCF (pH 5.5): 2.78; (6)ACD/BCF (pH 7.4): 3.65; (7)ACD/KOC (pH 5.5): 15.50; (8)ACD/KOC (pH 7.4): 20.35; (9)#H bond acceptors: 16; (10)#H bond donors: 4; (11)#Freely Rotating Bonds: 14; (12)Polar Surface Area: 217.05 Å²; (13)Index of Refraction: 1.629; (14)Molar Refractivity: 202.551 cm³; (15)Molar Volume: 569.852 cm³; (16)Polarizability: 80.298×10^-24cm³; (17)Surface Tension: 70.4 dyne/cm; (18)Density: 1.425 g/cm³; (19)Flash Point: 496.696 °C; (20)Enthalpy of Vaporization: 136.704 kJ/mol; (21)Boiling Point: 897.676 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.

When you are using this chemical, please be cautious about it as the following:
This chemical is toxic if swallowed. When using it, you need wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, you must seek medical advice immediately (show the label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: O=C2c1cc7c(c(O)c1C(=O)c3c2cccc3O)[C@@H](O[C@@H]6O[C@H]([C@@H](O[C@@H]5O[C@H]([C@@H](O[C@@H]4O[C@H](C(=O)CC4)C)[C@@H](O)C5)C)[C@@H](N(C)C)C6)C)C[C@](O)(CC)[C@@H]7C(=O)OC
(2)Std. InChI: InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
(3)Std. InChIKey: USZYSDMBJDPRIF-SVEJIMAYSA-N

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LDLo	intravenous	5mg/kg (5mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: FOOD INTAKE (ANIMAL)	Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980.
mammal (species unspecified)	LD50	intraperitoneal	25mg/kg (25mg/kg)		Antibiotiki. Vol. 29, Pg. 748, 1984.
mouse	LD50	intraperitoneal	16100ug/kg (16.1mg/kg)		Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985.
mouse	LD50	intravenous	16500ug/kg (16.5mg/kg)		Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985.
mouse	LD50	oral	30100ug/kg (30.1mg/kg)		Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985.
mouse	LD50	subcutaneous	22100ug/kg (22.1mg/kg)		Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 30, Pg. 918, 1985.
rat	LD50	intraperitoneal	17400ug/kg (17.4mg/kg)	BLOOD: CHANGES IN CELL COUNT (UNSPECIFIED) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Antibiotiki i Meditsinskaya Biotekhnologiya. Antibiotics and Medical Biotechnology. Vol. 32, Pg. 915, 1987.
rat	LD50	intravenous	25710ug/kg (25.71mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980.
rat	LD50	oral	58560ug/kg (58.56mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980.
rat	LD50	subcutaneous	20mg/kg (20mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: FOOD INTAKE (ANIMAL)	Japanese Journal of Antibiotics. Vol. 33, Pg. 138, 1980.